Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Aelis Farma S.A.S. is a biopharmaceutical company focused on the development of novel therapeutics for unmet medical needs. The company is particularly known for its pioneering research in developing specific CB1 receptor blockers that address pathologies related to neuropsychiatric and neurodevelopmental disorders. Aelis Farma's innovative approach targets disorders such as cannabis addiction, cognitive deficits related to Down syndrome, and other diseases associated with the endocannabinoid system. Operating within the dynamic field of biotechnology, Aelis Farma leverages advanced scientific research and clinical trials to advance its drug candidates through various stages of development. By addressing conditions with significant societal impacts, Aelis Farma plays a crucial role in the biopharmaceutical industry, striving to bring novel treatments to market that could significantly improve patient outcomes globally. Its work is vital in the medical community's ongoing efforts to tackle complex neuropsychological conditions.
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -€5M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€0.00
▼ -100.0% YoY
Net Income (TTM)
-€6M
▲ +13.7% YoY
Op. Margin
—
ROIC
-35.94%
▲ +0.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€5M
▲ +55.4% YoY
Op. Cash Flow (TTM)
-€5M
▲ +45.5% YoY
Net Debt
-€2M
Net Cash Position
Cash & Equiv.
€9M
Continue Research